FDA: Do Not Sell or Use Zantac, Cancer Concerns

Wire Service
By Wire Service
April 1, 2020Health
share
FDA: Do Not Sell or Use Zantac, Cancer Concerns
Packages and pills of Zantac, a popular medication which decreases stomach acid production and prevents heartburn, sit on a table in New York City, on Sept. 19, 2019. (Drew Angerer/Getty Images)

The Food and Drug Administration (FDA) is calling on manufacturers to immediately pull all ranitidine heartburn drugs, commonly known by the brand name Zantac from the market.

That includes both prescription and over-the-counter products.

The agency made the announcement Wednesday.

According to the FDA, an ongoing investigation found a contaminant in the medications can build up if stored at higher than normal temperatures.

Heartburn medication Zantac OTC
Heartburn medication Zantac OTC. (Screenshot via CNN)

The contaminant, NDMA, is a probable carcinogen—a substance that could cause cancer.

According to the New York Times, most manufacturers have already removed their products from the market, as have several major pharmacy chains.

The-CNN-Wire
™ & © 2020 Cable News Network, Inc., a WarnerMedia Company. All rights reserved.
ntd newsletter icon
Sign up for NTD Daily
What you need to know, summarized in one email.
Stay informed with accurate news you can trust.
By registering for the newsletter, you agree to the Privacy Policy.
Comments